26 September 2013 in Journal of the American Heart Association
Background: Stem cells for cardiac repair have shown promise in preclinical trials, but lower than expected retention, viability, and efficacy. Encapsulation is one potential strategy to increase viable cell retention while facilitating paracrine effects. Methods and Results: Human mesenchymal stem cells ( hMSC ) were encapsulated in alginate and attached to the heart with a hydrogel patch in a rat myocardial infarction ( MI ) model. Cells were tracked using bioluminescence ( BLI ) and cardiac function measured by transthoracic echocardiography ( TTE ) and cardiac magnetic resonance imaging ( CMR ). Microvasculature was quantified using von W illebrand factor staining and scar measured by M asson's T richrome. Post‐ MI ejection fraction by CMR was greatly improved in encapsulated hMSC ‐treated animals ( MI : 34±3%, MI +Gel: 35±3%, MI +Gel+ hMSC : 39±2%, MI +Gel+encapsulated hMSC : 56±1%; n=4 per group; P <0.01). Data represent mean± SEM . By TTE , encapsulated hMSC ‐treated animals had improved fractional shortening. Longitudinal BLI showed greatest hMSC retention when the cells were encapsulated ( P <0.05). Scar size at 28 days was significantly reduced in encapsulated hMSC ‐treated animals ( MI : 12±1%, n=8; MI +Gel: 14±2%, n=7; MI +Gel+ hMSC : 14±1%, n=7; MI +Gel+encapsulated hMSC : 7±1%, n=6; P <0.05). There was a large increase in microvascular density in the peri‐infarct area ( MI : 121±10, n=7; MI +Gel: 153±26, n=5; MI +Gel+ hMSC : 198±18, n=7; MI +Gel+encapsulated hMSC : 828±56 vessels/mm 2 , n=6; P <0.01). Conclusions: Alginate encapsulation improved retention of hMSC s and facilitated paracrine effects such as increased peri‐infarct microvasculature and decreased scar. Encapsulation of MSCs improved cardiac function post‐ MI and represents a new, translatable strategy for optimization of regenerative therapies for cardiovascular diseases.
1 March 2006 in Radiology
To retrospectively evaluate the natural history of high-grade (>50%) asymptomatic central venous stenosis (CVS) in hemodialysis patients and the outcome of serial treatment of CVS with percutaneous transluminal angioplasty (PTA). The institutional review board granted exemption for this retrospective study, the need for informed consent was waived, and all data collection was in compliance with HIPAA. Patients with hemodialysis access requiring maintenance procedures between 1998 and 2004 and incidentally found to have ipsilateral (> or =50%) CVS were identified from a departmental database. Thirty-five patients (19 men, 16 women; mean age, 58.7 years) with 38 grafts met inclusion criteria, and 86 venograms were reviewed. CVS was measured by using venograms obtained before and after PTA, if performed. Patients with arm swelling, multiple CVS, indwelling catheters, and stents at the first encounter were excluded. CVS progression was calculated by dividing the change in the degree of stenosis by the time between venographic examinations. Wilcoxon rank sum test was used to evaluate differences in rate of CVS progression between treated and nontreated patients. Mean degree of CVS before intervention was 71% (range, 50%-100%). Sixty-two percent (53 of 86) of lesions had associated collateral vessels; 28% (24 of 86) of CVSs were not treated. Mean degree of stenosis in this group was 72% (range, 30%-100%); mean progression was -0.08 percentage point per day. No untreated CVS progressed to symptoms, stent placement, or additional CVS. Seventy-two percent (62 of 86) of CVSs were treated with PTA. Mean degree of stenosis in this group was 74% (range, 50%-100%) before and 40% (range, 0%-75%) after treatment; mean progression was 0.21 percentage point per day after treatment (P = .03). Six (8%) of 62 treatments were followed by CVS escalation; one patient developed arm swelling, four required stents, and four developed additional CVS. PTA of asymptomatic CVS greater than 50% in the setting of hemodialysis access maintenance procedures was associated with more rapid stenosis progression and escalation of lesions, compared with a nontreatment approach.
21 December 2012 in Journal of Tissue Engineering and Regenerative Medicine
JOJuan Manuel Ortega-Legaspi
Juan Manuel Ortega-Legaspi
+4
Stem cell‐based therapies hold great promise as a clinically viable approach for vascular regeneration. Preclinical studies have been very encouraging and early clinical trials have suggested favourable outcomes. However, significant challenges remain in terms of optimizing cell retention and maintenance of the paracrine effects of implanted cells. To address these issues, we have proposed the use of a cellular encapsulation approach to enhance vascular regeneration. We contained human mesenchymal stem cells (hMSCs) in biocompatible alginate microcapsules for therapeutic treatment in the setting of murine hindlimb ischaemia. This approach supported the paracrine pro‐angiogenic activity of hMSCs, prevented incorporation of hMSCs into the host tissue and markedly enhanced their therapeutic effect. While injection of non‐encapsulated hMSCs resulted in a 22 ± 10% increase in vascular density and no increase in perfusion, treatment with encapsulated hMSCs resulted in a 70 ± 8% increase in vascular density and 21 ± 7% increase in perfusion. The described cellular encapsulation strategy may help to better define the mechanisms responsible for the beneficial effects of cell‐based therapies and provide a therapeutic strategy for inducing vascular growth in the adult. As hMSCs are relatively easy to isolate from patients, and alginate is biocompatible and already used in clinical applications, therapeutic cell encapsulation for vascular repair represents a highly translatable platform for cell‐based therapy in humans. Copyright © 2012 John Wiley & Sons, Ltd.
23 January 2018 in Journal of the American Heart Association
Background: During myocardial ischemia/reperfusion ( MI /R) injury, there is extensive release of immunogenic metabolites that activate cells of the innate immune system. These include ATP and AMP , which upregulate chemotaxis, migration, and effector function of early infiltrating inflammatory cells. These cells subsequently drive further tissue devitalization. Mesenchymal stromal cells ( MSC s) are a potential treatment modality for MI /R because of their powerful anti‐inflammatory capabilities; however, the manner in which they regulate the acute inflammatory milieu requires further elucidation. CD 73, an ecto‐5′‐nucleotidase, may be critical in regulating inflammation by converting pro‐inflammatory AMP to anti‐inflammatory adenosine. We hypothesized that MSC ‐mediated conversion of AMP into adenosine reduces inflammation in early MI /R, favoring a micro‐environment that attenuates excessive innate immune cell activation and facilitates earlier cardiac recovery. Methods and Results: Adult rats were subjected to 30 minutes of MI /R injury. MSC s were encapsulated within a hydrogel vehicle and implanted onto the myocardium. A subset of MSC s were pretreated with the CD 73 inhibitor, α,β‐methylene adenosine diphosphate, before implantation. Using liquid chromatography/mass spectrometry, we found that MSC s increase myocardial adenosine availability following injury via CD 73 activity. MSC s also reduce innate immune cell infiltration as measured by flow cytometry, and hydrogen peroxide formation as measured by Amplex Red assay. These effects were dependent on MSC ‐mediated CD 73 activity. Finally, through echocardiography we found that CD 73 activity on MSC s was critical to optimal protection of cardiac function following MI /R injury. Conclusions: MSC ‐mediated conversion of AMP to adenosine by CD 73 exerts a powerful anti‐inflammatory effect critical for cardiac recovery following MI /R injury.